Trssx stock Another product candidate in TG Therapeutics' pipeline is umbralisib, a novel, oral, once-daily inhibitor of PI3K delta. Umbralisib is being studied in combination with ublituximab for the treatment of CLL and MCL, as well as in combination with other drugs for the treatment of autoimmune diseases. TG Therapeutics has reported positive data from several clinical trials of its product candidates. In December 2020, the company announced positive top-line results from the UNITY-CLL Phase 3 trial of ublituximab in combination with umbralisib in patients with relapsed/refractory CLL. The trial met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) compared to the control arm. In addition to its clinical development efforts, TG Therapeutics has also been active in pursuing strategic partnerships and collaborations. In November 2020, the company announced a collaboration with BeiGene, Ltd. to develop and commercialize ublituximab and umbralisib in Greater China. Under the terms of the agreement, TG Therapeutics received an upfront payment of $60 million and is eligible to receive up to $350 million in milestone payments, as well as royalties on sales in Greater China. TG Therapeutics has also been active in pursuing regulatory approvals for its product candidates. In December 2020, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ublituximab in combination with umbralisib for the treatment of relapsed/refractory CLL. The FDA has granted Priority Review designation to the NDA, with a Prescription Drug User Fee Act (PDUFA) target action date of August 9, 2021. In summary, trssx stock, or TG Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company has a pipeline of investigational medicines, including ublituximab and umbralisib, which are being studied in combination with other drugs for the treatment of various types of blood cancer. TG Therapeutics has reported positive data from several clinical trials and has pursued strategic partnerships and collaborations to support the development and commercialization of its product candidates. The company is currently seeking regulatory approvals for its product candidates, including an NDA for ublituximab in combination with umbralisib for the treatment of relapsed/refractory CLL. ipsy is known for partnering with both established and emerging beauty brands, ensuring that subscribers receive a well-rounded assortment of products. For the July 2024 Glam Bag, ipsy is expected to collaborate with the following brands:
11. Sbarro: For a taste of New York-style pizza, Sbarro serves up slices of pizza by the slice, as well as other Italian dishes like pasta and calzones.